# Oxford Brain Diagnostics part of an International Consortium Awarded Grant from The Michael J. Fox Foundation for diffusion MRI Techniques to Detect Pre-Symptomatic Parkinson's Disease

**02 June 2025, Oxford, United Kingdom.** An international research consortium brings together expertise from Oxford Brain Diagnostics, University of California San Francisco, University of Florida, Massachusetts General Hospital (Harvard Medical School) and Hospital du Sacré-Cœur de Montréal to validate and standardise diffusion MRI (dMRI) measures as imaging biomarkers to improve the diagnosis and monitoring of Parkinson's disease. This 24-month collaborative research project is awarded a $650,000 grant by The Michael J. Fox Foundation for Parkinson's Research (MJFF).

Oxford Brain Diagnostics, (OBD), a pioneer in developing proprietary diagnostic tools for measuring neurodegeneration, will provide valuable insights into cortical microstructure with Cortical Disarray Measurement (CDM®). Using standard MRI images, the software provides a quantifiable measure of neurodegeneration, independent of the disease mechanism, and has recently been given FDA 510k clearance for clinical use for CDM Insights.

*"We're proud to be part of this international consortium,"* said Dr. Steven Chance, CEO and co-founder of Oxford Brain Diagnostics. *"Receiving grant funding from MJFF is a testament to the potential impact this study aims to bring to patients. This work will contribute to a more biologically grounded approach to the diagnosis and treatment of Parkinson's — with the potential to integrate into the NSD-ISS and other new diagnostic frameworks, improving outcomes for people living with the disease."*

Parkinson's disease and related synucleinopathies remain difficult to diagnose, monitor and evaluate due to their complex and varied pathophysiology. The consortium aims to address these challenges by validating two advanced MRI biomarkers (Free water and CDM) as objective, non-invasive indicators of early neurodegenerative changes and inflammation in the brain.

The outcomes of the project are expected to make meaningful impact — enabling better patient stratification for clinical trials, providing validated biomarkers to objectively measure treatment effects, and offering clinicians a tool to monitor disease progression and response over time.

**About Oxford Brain Diagnostics Ltd** - Oxford Brain Diagnostics Ltd is rethinking how brain health is assessed and managed. Founded in neuropathological and neuroimaging expertise, the company's Cortical Disarray Measurement (CDM®) technology uses MRI brain scan data to create products to support early and differential diagnosis, track progression, and predict the decline due to neurodegenerative diseases. Oxford Brain Diagnostics is committed to assessing brain health based on changes in the cellular structure, supporting drug development, and helping clinicians around the world in their fight to defeat Alzheimer's and other neurodegenerative diseases.

For more information, visit www.oxfordbraindiagnostics.com

Contact: Omar Ehsan, Chief Commercial Officer; omar.ehsan@oxfordbraindiagnostics.com